Stay updated on SYNT001 Safety in Warm Autoimmune Hemolytic Anemia Clinical Trial

Sign up to get notified when there's something new on the SYNT001 Safety in Warm Autoimmune Hemolytic Anemia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SYNT001 Safety in Warm Autoimmune Hemolytic Anemia Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:39:36.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the number of participants planned to receive IV doses of ALXN1830 (SYNT001 Dose 1) in a safety study for participants with Warm Autoimmune Hemolytic Anemia.
    Difference
    0.1%
    Check dated 2024-06-06T14:38:10.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying the need for informed consent and a confirmed diagnosis of WAIHA, among other criteria. Previously, no information was provided regarding participation criteria for collaborators and investigators.
    Difference
    18%
    Check dated 2024-05-22T21:20:17.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:40:49.000Z thumbnail image

Stay in the know with updates to SYNT001 Safety in Warm Autoimmune Hemolytic Anemia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SYNT001 Safety in Warm Autoimmune Hemolytic Anemia Clinical Trial page.